Leukemia & lymphoma/Leukemia and lymphoma · 2020 · 20 citations · 34 references
MedicineImmunologyOncologyCancer ImmunologyMolecular OncologyPediatric OncologyCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint RegulationLymphoid NeoplasmsPediatric LymphomasTumor-infiltrating LymphocytesImmune Checkpoint LigandsImmune Checkpoint ResistanceImmune Checkpoint ResponseLymphocyte PhenotypingLymphocyte SubtypesPatient Outcome EvaluationPatient Outcome MeasurementPd-l1 Blockade
inhibition of T cell proliferation and activation. It has been demonstrated to be overexpressed on tumor infiltrating lymphocytes (TILs) of a variety of cancers with associated poor outcomes. The purpose of this study is to characterize the expression pattern and clinical significance of LAG-3 in pediatric Hodgkin lymphoma (HL). Patient tumor samples from Children's Oncology Group clinical trial AHOD0031 with matched patient outcome data were analyzed for the expression of LAG-3 and PD-L1 using immunohistochemistry. 73/115 patients (63%) demonstrated positive LAG-3 staining. No demographic or survival outcome data were significantly associated with LAG-3 expression. Interestingly, patients with the lowest density of expression were found to have the worst EFS, and those with highest density of expression demonstrated the best EFS. There was a positive statistically significant relationship between presence of LAG-3 and PD-L1 expression. This project is innovative in its characterization of LAG-3 as an immune checkpoint target in pediatric HL.
34